Responses of DSIP in Sleep Pattern Regulation

by | Aug 10, 2022 | Research


Delta Sleep Inducing Peptide (DSIP) is a neuropeptide that influences various endocrine and physiological functions in the nervous system. The peptide was isolated in 1977 from the brains of rats during slow-wave sleep.

DSIP can lower oxidative stress and restore normal myocardial contractility. Furthermore, the peptide can potentially treat major depressive disorders and cancer. DSIP also inhibits Somatostatin secretion, modifies corticotropin levels, maintains normal blood pressure, prevents stress, regulates sleep patterns, and regulates pain perception.


DSIP and Sleep Pattern Regulation

Some research suggests DSIP promotes slow-wave sleep while suppressing paradoxical sleep. It can also cause arousal in the first hour of sleep and sedation in the second. Research findings suggest that DSIP can normalize sleep and modulate sleep cycle dysfunctions.
Sleep research involving DSIP was conducted in models with chronic insomnia, and DSIP improved sleep to the same level as normal controls. This study supports previous findings that DSIP reduces sleep latency and promotes sleep structure in chronic insomnia.[4] The scientists note that “The treatment substantially improved night sleep with the first and additionally with repeated doses.”
DSIP research in humans has shown that the peptide promotes sleep. According to the research, DSIP induces sleepy feelings, increases sleep time by 59% compared to a placebo, and delays sleep onset.[5] These findings, however, contradict the EEG analysis, which revealed no sedation. However, this could be due to current testing patterns, as many EEG measures of sedation are based on pharmacologic sedation rather than natural sedation.


How DSIP May Impact Metabolism

DSIP research in rat models shows that the peptide limits stress-induced metabolic disturbances that cause the mitochondria to switch from oxygen-dependent to oxygen-independent respiration. The latter produces dangerous metabolic byproducts. DSIP may be beneficial in conditions such as heart attack and stroke due to its ability to maintain oxidative phosphorylation even in hypoxic conditions.[8]
DSIP can mitigate metabolic damage caused by oxygen deprivation by preserving normal mitochondrial function, thereby protecting tissues until blood flow is restored.
DSIP can reduce free radical production by maintaining normal mitochondrial functions, making the peptide an extremely potent anti-aging factor.


DSIP Impact on Physiological Functions

DSIP research shows that the peptide inhibits somatostatin secretion, contributing to skeletal muscle hypertrophy and hyperplasia.
According to Delta Sleep Inducing Peptide research, the peptide can influence blood pressure, thermogenesis, the lymphokine system, and heart rate.

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.



  1. Popovich IG, Voitenkov BO, Anisimov VN, Ivanov VT, Mikhaleva II, Zabezhinski MA, Alimova IN, Baturin DA, Zavarzina NY, Rosenfeld SV, Semenchenko AV, Yashin AI. Effect of delta-sleep inducing peptide-containing preparation Deltaran on biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice. Mech Ageing Dev. 2003 Jun;124(6):721-31. doi: 10.1016/s0047-6374(03)00082-4. PMID: 12782416.
  2. A. B. Sinyukhin, G. P. Timoshinov, V. A. Kornilov, and P. D. Shabanov, “P.7.a.006 Delta sleep-inducing peptide analogue corrects the CNS functional state of children treated with antiblastomic therapy,” Eur. Neuropsychopharmacol., vol. 19, pp. S681–S682, Sep. 2009.
  3. E. V. Koplik et al., “Delta sleep-inducing peptide and Deltaran: potential approaches to antistress protection,” Neurosci. Behav. Physiol., vol. 38, no. 9, pp. 953–957, Nov. 2008
  4. Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. Eur Neurol. 1987;27(2):120-9. doi: 10.1159/000116143. PMID: 3622582.
  5. Schneider-Helmert D, Gnirss F, Monnier M, Schenker J, Schoenenberger GA. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. Int J Clin Pharmacol Ther Toxicol. 1981 Aug;19(8):341-5. PMID: 6895513.
  6. Larbig W, Gerber WD, Kluck M, Schoenenberger GA. Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study. Eur Neurol. 1984;23(5):372-85. doi: 10.1159/000115716. PMID: 6548970.
  7. Nakamura A, Nakashima M, Sugao T, Kanemoto H, Fukumura Y, Shiomi H. Potent antinociceptive effect of centrally administered delta-sleep-inducing peptide (DSIP). Eur J Pharmacol. 1988 Oct 18;155(3):247-53. doi: 10.1016/0014-2999(88)90510-9. PMID: 2853064.
  8. Khvatova EM, Samartzev VN, Zagoskin PP, Prudchenko IA, Mikhaleva II. Delta sleep inducing peptide (DSIP): effect on respiration activity in rat brain mitochondria and stress protective potency under experimental hypoxia. Peptides. 2003 Feb;24(2):307-11. doi: 10.1016/s0196-9781(03)00040-8. PMID: 12668217.